After pretty much exactly 5 years at the IZB, adivo GmbH, a leader in the discovery of species-specific therapeutic antibodies for pets, has embarked on the next phase of its corporate development and moved into new headquarters in Puchheim, near Munich. Preparations for a move to new premises began as early as mid-2022, and the move will triple the office and laboratory space available to the antibody expert to around 1,000 square meters. In addition to steady employee growth, the maturing development pipeline and adivo’s success in research alliances have contributed to the increased space requirements.
In addition, the company recently announced that the first animal patients have been treated in a clinical trial evaluating the safety and early signs of efficacy of an antibody program developed by adivo. The cancer antibody, which is fully tailored version for dogs and addresses an established immuno-oncology pathway, is adivo’s first proprietary program to enter first-in-patient studies. The clinical trial will recruit dogs with late-stage solid tumors, including inoperable and metastatic cases treated under compassionate use.
